Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI
Schizophrenia
About this trial
This is an interventional basic science trial for Schizophrenia
Eligibility Criteria
Inclusion Criteria:
Inclusion Criteria for Schizophrenia/Schizoaffective Subjects
- Men and women between ages of 18 to 60 inclusive, of any ethnic origin.
- Subjects must be right handed.
- DSM IV criteria for chronic schizophrenia or schizoaffective disorder.
- Good physical health as determined by complete physical examination, laboratory tests, and EKG
Inclusion Criteria for Healthy Control Subjects:
1. Fifteen individuals, matched to the patient subjects on the basis of age, gender, parental SES, handedness.
Exclusion Criteria:
Exclusion Criteria for Schizophrenia/Schizoaffective Subjects
- Previous poor response or adverse side effects to thiothixene, olanzapine or risperidone.
- Left handedness
- Epilepsy, HIV, or current myeloproliferative disorder
- Current severe major depression.
- Current or past history of Substance Dependence (except caffeine or nicotine)
- Criteria for active Substance Abuse within past 30 days
- Learning disability
- Mental Retardation
- Foreign metal objects or implants as determined by MRI safety questionnaires
- If judged unsuitable for the study based on other medical or psychiatric condition according to the PIs best clinical judgment.
- No depot neuroleptic within 60 days before the day of randomization.
- Women who are pregnant or breastfeeding, and/or unwilling to take a pregnancy test.
Exclusion Criteria for Healthy Control Subjects
1. History of psychiatric disorder or current medical illness
Sites / Locations
- Unc Psychiatry
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
No Intervention
Risperidone Treatment Group
Olanzapine Treatment Group
Thiothixene
A two-week cross-titration phase followed randomization when patients started treatment with Risperidone in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose was 6mg/day or highest dose tolerated.
A two-week cross-titration phase followed randomization when patients started treatment with Olanzapine in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose 20mg/day (or the highest dose tolerated) for 8 weeks, following 4 weeks of baseline Thiothixene.
Subjects were first stabilized on open-label Thiothixene for four weeks, target dose 25 mg per day. Patients were then randomized to either Risperidone or Olanzapine treatment for 8 weeks.